FDA Approves First Gene Therapy to Treat Adults with Hemophilia B (Cell and Gene Therapy Catapult - Regulatory Round-up – November 2022)
Fiche du document
25 janvier 2023
- handle: 10670/1.kauyb0
Sujets proches
Therapy, GeneCiter ce document
adelage, « FDA Approves First Gene Therapy to Treat Adults with Hemophilia B (Cell and Gene Therapy Catapult - Regulatory Round-up – November 2022) », ELSIBI, ID : 10670/1.kauyb0
Métriques
Partage / Export
Résumé
On the 22nd of November 2022, FDA approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes. Please find more details of the announcement here. See all of Catapult's Regulatory Round-up for November 2022 here. Pu...